Received Nov 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | 026L2CA | IM |
MS symptoms, brain demyelination and lesion, balance issues, dizziness, atrial tachycardia, positive for 2 matching oligoclonal bands in serum and CSF indicating systematic inflammation, headaches, neurological issues; Atrial tachycardia; This spontaneous case was reported by a consumer and describes the occurrence of MULTIPLE SCLEROSIS (MS symptoms, brain demyelination and lesion, balance issues, dizziness, atrial tachycardia, positive for 2 matching oligoclonal bands in serum and CSF indicating systematic inflammation, headaches, neurological issues) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L2CA) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. No Medical History information was reported. On 05-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) .5 milliliter. On 07-Jan-2021, the patient experienced MULTIPLE SCLEROSIS (MS symptoms, brain demyelination and lesion, balance issues, dizziness, atrial tachycardia, positive for 2 matching oligoclonal bands in serum and CSF indicating systematic inflammation, headaches, neurological issues) (seriousness criterion medically significant) and ATRIAL TACHYCARDIA (Atrial tachycardia). At the time of the report, MULTIPLE SCLEROSIS (MS symptoms, brain demyelination and lesion, balance issues, dizziness, atrial tachycardia, positive for 2 matching oligoclonal bands in serum and CSF indicating systematic inflammation, headaches, neurological issues) and ATRIAL TACHYCARDIA (Atrial tachycardia) had not resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) was unknown. Concomitant medication use information was not provided by reporter. The current age of the patient was reported as 38 years. It is unknown if the patient experienced any additional symptoms/events. Treatment medication use information was not provided by reporter.; Reporter's Comments: Company Comment: The benefit-risk relationship of product is not affected by this report.